Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
70.84 USD | +0.04% |
|
+4.83% | -12.59% |
12:26pm | Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating | MT |
11/07 | Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.59% | 88.22B | |
+63.05% | 856B | |
+39.45% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+5.48% | 234B | |
+16.47% | 226B | |
+14.63% | 177B | |
+1.08% | 165B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Transcript : Gilead Sciences, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 11